Daily Stock Analysis, EBS, Emergent BioSolutions Inc, priceseries

Emergent BioSolutions Inc. Daily Stock Analysis
Stock Information
Open
54.59
Close
54.82
High
54.88
Low
54.06
Previous Close
54.35
Daily Price Gain
0.47
YTD High
67.46
YTD High Date
Feb 22, 2019
YTD Low
39.11
YTD Low Date
Aug 27, 2019
YTD Price Change
-2.88
YTD Gain
-4.99%
52 Week High
73.89
52 Week High Date
Dec 3, 2018
52 Week Low
39.11
52 Week Low Date
Aug 27, 2019
52 Week Price Change
-16.45
52 Week Gain
-23.08%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 8. 2017
43.55
Dec 29. 2017
46.70
14 Trading Days
7.23%
Link
LONG
Aug 29. 2019
42.44
Sep 13. 2019
51.80
10 Trading Days
22.04%
Link
Company Information
Stock Symbol
EBS
Exchange
NYSE
Company URL
http://www.emergentbiosolutions.com
Company Phone
240-631-3200
CEO
Daniel J. Abdun-Nabi
Headquarters
Maryland
Business Address
400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD 20879
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001367644
About

Emergent BioSolutions Inc. is a global specialty biopharmaceutical company focused on the development, manufacture and distribution of a portfolio of medical countermeasures (vaccines, therapeutics and other novel products) and related services for civilian and military populations that address intentional and naturally emerging public health threats, specifically Chemical, Biological, Radiological, Nuclear and Explosive, or CBRNE, threats as well as emerging infectious diseases. The company operations include manufacturing, regulatory affairs, quality assurance, quality control, international sales and marketing and domestic government affairs in support of its portfolio of marketed products, as well as product development and manufacturing infrastructure in support of its portfolio of investigational stage product candidates. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Description

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.